Barcelona-Based SpliceBio Raises €119M to Target Stargardt Disease

Published on Spencer Knight via LinkedIn

SpliceBio has secured €119 million in Series B funding, the largest ever for a biotech in Catalonia. The funds will accelerate SB-007, their lead candidate for Stargardt disease, an inherited retinal disorder caused by mutations in the ABCA4 gene, for which there are currently no approved therapies.

The company uses an advanced protein splicing approach to repair gene errors and deliver dual-function therapy. Spencer Knight highlights the deal as a major boost for European biotech and a meaningful milestone in the race to treat rare forms of vision loss.

Read the full article via Sifted:

👉 SpliceBio closes €119 million round, the largest for a biotech company in Catalonia

Images used are for illustrative purposes only and do not depict actual persons, products, or facilities. For full details, please refer to the original article via the provided link.